209 related articles for article (PubMed ID: 30701031)
1. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
[TBL] [Abstract][Full Text] [Related]
2. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
3. A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells.
Grundy M; Al-Kaisi F; Cull J; Williams C; Smith D; Seedhouse CH
EJHaem; 2021 Feb; 2(1):40-47. PubMed ID: 35846088
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells.
Cho H; Jang JE; Eom JI; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
Exp Hematol Oncol; 2021 Apr; 10(1):28. PubMed ID: 33858507
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.
Yao MY; Wang YF; Zhao Y; Ling LJ; He Y; Wen J; Zheng MY; Jiang HL; Xie CY
Am J Cancer Res; 2022; 12(8):3829-3842. PubMed ID: 36119822
[TBL] [Abstract][Full Text] [Related]
6. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer.
Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K
Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717
[TBL] [Abstract][Full Text] [Related]
8. Combined venetoclax and alvocidib in acute myeloid leukemia.
Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
[TBL] [Abstract][Full Text] [Related]
9. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
Griffioen MS; de Leeuw DC; Janssen JJWM; Smit L
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884517
[TBL] [Abstract][Full Text] [Related]
10. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
11. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
[TBL] [Abstract][Full Text] [Related]
12. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
13. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
14. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines.
Abdul Rahman SF; Muniandy K; Soo YK; Tiew EYH; Tan KX; Bates TE; Mohana-Kumaran N
Biochem Biophys Rep; 2020 Jul; 22():100756. PubMed ID: 32346617
[TBL] [Abstract][Full Text] [Related]
15. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
[TBL] [Abstract][Full Text] [Related]
16. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML.
Wang Q; Hao S
Oncol Lett; 2019 Nov; 18(5):5481-5489. PubMed ID: 31612056
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism.
Li G; Li D; Yuan F; Cheng C; Chen L; Wei X
Ann Transl Med; 2021 Oct; 9(20):1575. PubMed ID: 34790781
[TBL] [Abstract][Full Text] [Related]
18. Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia.
Zhou FJ; Zeng CX; Kuang W; Cheng C; Liu HC; Yan XY; Chen XP; Zhou G; Cao S
J Cancer; 2021; 12(22):6727-6739. PubMed ID: 34659562
[No Abstract] [Full Text] [Related]
19. Molecular mechanisms by which splice modulator GEX1A inhibits leukaemia development and progression.
Sellin M; Mack R; Rhodes MC; Zhang L; Berg S; Joshi K; Liu S; Wei W; S J PB; Larsen P; Taylor RE; Zhang J
Br J Cancer; 2022 Jul; 127(2):223-236. PubMed ID: 35422078
[TBL] [Abstract][Full Text] [Related]
20. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]